In conclusion, we found that aberrant expression of important components of the IGFR-mediated signaling pathway, and especially the IGF1R-alpha/IGF2R combination, are associated with better clinical outcomes in patients with hormone-receptor positive, HER2-negative, node-positive early breast cancer. The gene discussed is IGF1R; the disease is breast cancer.